https://web.archive.org/web/20260702142413/https://www.functionalmedicinenorthernvirginia.com/
View dossier →John David Ratcliffe alias The Root Cause Chiropractor
Website · functionalmedicinenorthernvirginia.com
Practice location
880 West Church Road
Sterling, VA 20164
Funnel-first framing that runs on persuasion, light on published evidence.
Oh, look at John Ratcliffe, the 'elite physician' who's one of the few Chiropractors to treat MS, Diabetes, and Autoimmune diseases! He's so 'unrivaled' that insurance won't even cover his 'Functional Medicine' magic, which is probably just a fancy way to sell you supplements and labs. He's the 'Root Cause Chiropractor' who's so desperate to be a doctor that he'll treat anything, even if it's not his scope, because he's got a 'Functional Medicine Roadmap' to sell you.
High grift signals
Score breakdown
Direct answer
John David Ratcliffe is licensed in Virginia as a chiropractor (DC), not as an MD or DO, and Virginia's chiropractic scope statute (Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929 (prohibition on practicing medicine without a license)) limits that license to musculoskeletal care, not the diagnosis or treatment of systemic disease. Even so, they advertise diagnosing or treating Type 1 and 2 Diabetes, Depression/Anxiety, Treatment of MS, RA, SLE (Autoimmune), Neurological Disorders and Neuropathy, and Post Covid Long Haul Symptoms, conditions that belong with rheumatologists. Those same pages route patients toward paid programs that John David Ratcliffe profits from.
Key findings
- False Authority: Ratcliffe uses the term 'physicians' to describe himself as a Chiropractor (DC), conflating his narrow chiropractic license with the broad authority of an MD/DO. This is a classic false authority tactic to imply he can treat systemic disease like a medical doctor.see section ↓
- Claim "Autoimmune and inflammatory disorders (MS, RA, Thyroid, SLE, Etc.)": mixed in the medical literature.see section ↓
- Claim "Type 1 and 2 Diabetes": mixed in the medical literature.see section ↓
- NPI registry confirms JOHN DAVID RATCLIFFE as Chiropractor (DC) in Virginia (NPI 1730280363).see section ↓
- John David Ratcliffe shows credential inflation relative to stated vs likely credentials.see section ↓
- Dr John David Ratcliffe is marketed with a doctor title, but reviewed credentials indicate Chiropractor (DC) rather than an MD/DO physician license.see section ↓
- Against Virginia Board of Medicine, Chiropractic Advisory Board scope rules (Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929 (prohibition on practicing medicine without a license)), these advertised activities appear outside John David…see section ↓
- 18 of 19 advertised activities fall outside permitted Chiropractor scope in VA.see section ↓
Claims & evidence
13 advertised conditions or treatments fall outside their license scope. Each box leads with state-board scope notation; literature cross-check follows when we matched a specific claim. Every card carries its receipts: the quoted wording, a live source link, and an archived copy.
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Autoimmune and inflammatory disorders (MS, RA, Thyroid, SLE, Etc.).
Autoimmune and inflammatory disorders (MS, RA, Thyroid, SLE, Etc.)
- Supports
- The core of the influencer’s claim – that conditions such as multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroid disease, and systemic lupus erythematosus (SLE) are autoimmune and inflammatory disorders – is strongly supported by high‑quality evidence and major guidelines. [2][4] Systemic reviews and contemporary overviews classify SLE, RA, autoimmune thyroiditis (Hashimoto’s and Graves’ disease), and MS as prototypical autoimmune inflammatory diseases with either systemic or organ‑specific immune‑mediated tissue damage, driven by dysregulated T cells, B cells, autoantibodies, and pro‑inflammatory cytokines. Major rheumatology and lupus guidelines (EULAR/ACR, American College of Rheumatology, national SLE guidelines) consistently describe RA and SLE as chronic autoimmune inflammatory rheumatic diseases that require immunomodulatory or immunosuppressive therapy. [1] Autoimmune thyroid disease is similarly described in authoritative reviews as a common organ‑specific autoimmune disorder (3–5% prevalence) with a characteristic autoimmune pathogenesis (thyroid antigen recognition, lymphocytic infiltration, TPO/Tg antibodies, TRAb in Graves). [3] High‑quality observational and mechanistic data show clustering and co‑occurrence of autoimmune diseases (e. g. , autoimmune thyroid disease with RA and SLE, and the broader concept of multiple autoimmune syndrome), supporting the notion of a shared autoimmune background across these disorders. The systematic review and meta‑analysis on oral lichen planus (OLP) and autoimmune disorders further demonstrates statistically significant associations between OLP and autoimmune thyroid disease and other autoimmune conditions, reinforcing the broader idea of interconnected autoimmune and inflammatory pathology. Cardiovascular research, including the JACC meta‑analysis on global longitudinal strain and related case–control work, shows that chronic autoimmune inflammatory diseases such as RA and SLE are associated with subclinical myocardial dysfunction, confirming clinically relevant systemic inflammation beyond the primary target organs.
- Contradicts
- There is no high‑quality evidence or major guideline contradicting the basic classification of MS, RA, autoimmune thyroid disease, and SLE as autoimmune and inflammatory disorders; on the contrary, they are model diseases in this category. Where evidence is weaker is when broad influencer claims imply that all inflammatory or chronic conditions are autoimmune, or that simple lifestyle interventions alone can reliably prevent, reverse, or cure these autoimmune disorders; current clinical practice guidelines and therapeutic reviews emphasize the need for disease‑specific immunomodulatory or immunosuppressive treatments, often combined with but not replaced by lifestyle measures. [1][2][3][4] The OLP meta‑analysis and follow‑up reviews highlight that although OLP is associated with autoimmune diseases such as Hashimoto’s thyroiditis, the direction of causality and mechanistic pathways remain uncertain, and the evidence is described as weak to moderate rather than definitive, cautioning against over‑interpretation of these associations. Similarly, while multiple autoimmune syndrome and clustering of autoimmune diseases are documented, these data do not support claims that one autoimmune disease universally causes another or that they can all be managed in identical ways; instead, genetic, environmental, and immunologic susceptibility is complex and incompletely understood.
- Mainstream view
- The mainstream medical and scientific view is that multiple sclerosis, rheumatoid arthritis, autoimmune thyroid disease (e. [4] g. , Hashimoto’s thyroiditis, Graves’ disease), systemic lupus erythematosus, and related conditions are well‑defined autoimmune and inflammatory disorders, either systemic (such as SLE and RA) or organ‑specific (such as autoimmune thyroiditis). [2] Standard classifications group these diseases under autoimmune inflammatory rheumatic diseases or organ‑specific autoimmune diseases, and major international criteria (ACR/EULAR for RA and SLE, McDonald criteria for MS, established criteria for autoimmune thyroid disease) are used worldwide for diagnosis. [1][3] Pathophysiologically, mainstream consensus emphasizes dysregulated adaptive immunity (autoreactive T and B cells), autoantibody production, and pro‑inflammatory cytokine networks Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Autoimmune and inflammatory disorders (MS, RA, Thyroid, SLE, Etc.)”
Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929 (prohibition on practicing medicine without a license)
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Type 1 and 2 Diabetes.
Type 1 and 2 Diabetes
- Supports
- High-quality guidelines and consensus statements consistently support that type 1 and type 2 diabetes are distinct conditions in pathophysiology, natural history, and management, and both require structured, evidence-based care. ADA/EASD consensus for adults with type 1 diabetes and major society guidelines recommend intensive insulin therapy (multiple daily injections or insulin pump), frequent glucose monitoring (including CGM), diabetes self‑management education, and individualized glycemic targets, typically aiming around HbA1c <7% for most non‑pregnant adults.[1][2][3][5][19][22] For type 2 diabetes, multiple systematic reviews and umbrella reviews show that dietary interventions (very low energy diets, liquid meal replacement, Mediterranean, plant‑based, high protein, low‑glycaemic index diets) can improve glycemic control, reduce weight, and in some cases induce remission of type 2 diabetes, particularly in early disease and with significant weight loss.[0][20][15][23] The Diabetologia umbrella review indexed in the user’s list concludes that very low‑energy diets and formula meal replacements are among the most effective approaches for weight management and diabetes remission in adults with type 2 diabetes.[0] A large meta‑analysis of intensive glycaemic control in type 2 diabetes (BMJ d8277) finds that targeting lower HbA1c (around or below 7%) reduces microvascular complications and some composite macrovascular outcomes compared with more relaxed glycaemic control, supporting the principle that improving glycaemic control is beneficial, though benefits must be balanced against risks.[4][13][16][21] Major guidelines for diabetes care (e.g., ADA Standards of Care) endorse the classification of diabetes into type 1 and type 2, stress the importance of individualized glycemic targets, and integrate diet, physical activity, pharmacologic therapy, and cardiovascular risk management as core components of care.[2][3][11]
- Contradicts
- Evidence does not support viewing type 1 and type 2 diabetes as a single, homogeneous condition or assuming they can be managed interchangeably. Type 1 diabetes guidelines emphasize lifelong dependence on exogenous insulin due to autoimmune beta‑cell destruction; dietary changes alone cannot reverse or cure type 1 diabetes, and complete insulin withdrawal is not considered safe or evidence‑based.[1][5][9][19][22] In contrast, remission is documented and increasingly recognized for type 2 diabetes, typically via significant weight loss and intensive lifestyle or metabolic interventions, highlighting a fundamental difference in reversibility.[0][15][20][23] The BMJ meta‑analysis on intensive glycaemic control in type 2 diabetes shows that while tighter control can reduce some vascular endpoints, it significantly increases severe hypoglycaemia (about 30% higher risk), indicating that very aggressive glycaemic targets are not universally beneficial and may be harmful for many patients.[4][13][16][21][24] These data contradict any simplistic claim that “lower is always better” for glucose in all people with type 2 diabetes. Umbrella reviews and guidelines also show heterogeneity in response to diets for type 2 diabetes; no single dietary pattern is universally superior, and the certainty of evidence for remission and long‑term outcomes varies from low to moderate, underscoring that strong, uniform claims about diet‑based cures are not well supported.[0][20][23]
- Mainstream view
- Mainstream medical and scientific consensus is that type 1 and type 2 diabetes are distinct diseases that share chronic hyperglycaemia and elevated cardiometabolic risk but differ in etiology, typical age of onset, and treatment approach. Type 1 diabetes is primarily an autoimmune, insulin‑deficient condition requiring lifelong insulin therapy, structured self‑management education, frequent glucose monitoring, and comprehensive risk‑factor control; remission or cure through diet alone is not recognized.[1][5][9][19][22] Type 2 diabetes is characterized by insulin resistance and relative insulin deficiency, strongly linked to obesity and lifestyle factors. Evidence‑based management emphasizes lifestyle changes (dietary modification, physical activity, weight loss), metformin and other glucose‑lowering agents, and individualized escalation including insulin if needed.[2][3][20] For type 2 diabetes, high‑quality reviews and guidelines now acknowledge that remission is achievable in a subset of patients, particularly with substantial, sustained weight loss via very low‑energy diets, bariatric surgery, or intensive lifestyle/metabolic programs, but long‑term durability and applicability to all patients remain limited.[0][15][20][23] Major guidelines endorse individualized glycaemic targets (often HbA1c
“Type 1 and 2 Diabetes”
Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Gut dysfunction (gas, bloating, IBS, SIBO, IBD, GERD/reflux, celiac).
Gut dysfunction (gas, bloating, IBS, SIBO, IBD, GERD/reflux, celiac)
- Supports
- The claim is broad and partly descriptive rather than a testable treatment claim. [14] High-quality evidence and guidelines support that gas and bloating are common symptoms in IBS, and that IBS commonly overlaps symptomatically with celiac disease and can mimic IBD or GERD-related complaints; major IBS guidance recommends celiac serology in IBS with diarrhea and inflammatory markers to exclude IBD, reflecting this overlap. [7][8][16] Gut-directed treatments can improve bloating in IBS, and clinical guideline summaries note low-FODMAP diets, rifaximin in IBS-D, and some prescription agents can improve bloating symptoms. SIBO is recognized as a possible contributor to bloating/IBS-like symptoms, and current evidence-based reviews state breath testing may be useful when clinical suspicion supports it. [6][13]
- Contradicts
- The claim is too nonspecific to be strongly supported as written because it groups together several different disorders with different mechanisms and levels of evidence. [14] IBS is a disorder of gut-brain interaction, not simply ‘gut dysfunction,’ and bloating is common but not required for diagnosis; routine SIBO testing is not recommended without specific suspicion, which limits any general claim that these symptoms broadly indicate SIBO. [15] Celiac disease, IBD, and GERD are distinct diagnoses with specific diagnostic criteria, so the presence of gas or bloating alone does not establish them. [16] The evidence base for using one broad label to explain all of these conditions is weak, because symptom overlap is common but nonspecific, and guidelines instead emphasize targeted evaluation to distinguish them. [7] The provided index papers are mostly nutrition and IBD guidance, and they do not directly support the claim as a unified medical entity. [13]
- Mainstream view
- Mainstream medicine treats gas, bloating, IBS, SIBO, IBD, GERD/reflux, and celiac disease as overlapping but distinct conditions. Gas and bloating are common symptoms across several of these disorders, but they are not diagnostic by themselves; clinicians use symptom patterns plus targeted testing to differentiate functional disorders such as IBS from inflammatory disease, celiac disease, reflux disease, or suspected SIBO. [8][14][16]
“Gut dysfunction (gas, bloating, IBS, SIBO, IBD, GERD/reflux, celiac)”
Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Depression/Anxiety.
Depression/Anxiety
No specific health claims of theirs were cross-checked against the literature.
“Depression/Anxiety”
Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Functional Medicine for Autoimmune/Neurological Disorders.
Functional Medicine for Autoimmune/Neurological Disorders
No specific health claims of theirs were cross-checked against the literature.
“Functional Medicine”
Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Treatment of Type 1 and 2 Diabetes.
Treatment of Type 1 and 2 Diabetes
- Supports
- High-quality guidelines and consensus statements consistently support that type 1 and type 2 diabetes are distinct conditions in pathophysiology, natural history, and management, and both require structured, evidence-based care. ADA/EASD consensus for adults with type 1 diabetes and major society guidelines recommend intensive insulin therapy (multiple daily injections or insulin pump), frequent glucose monitoring (including CGM), diabetes self‑management education, and individualized glycemic targets, typically aiming around HbA1c <7% for most non‑pregnant adults.[1][2][3][5][19][22] For type 2 diabetes, multiple systematic reviews and umbrella reviews show that dietary interventions (very low energy diets, liquid meal replacement, Mediterranean, plant‑based, high protein, low‑glycaemic index diets) can improve glycemic control, reduce weight, and in some cases induce remission of type 2 diabetes, particularly in early disease and with significant weight loss.[0][20][15][23] The Diabetologia umbrella review indexed in the user’s list concludes that very low‑energy diets and formula meal replacements are among the most effective approaches for weight management and diabetes remission in adults with type 2 diabetes.[0] A large meta‑analysis of intensive glycaemic control in type 2 diabetes (BMJ d8277) finds that targeting lower HbA1c (around or below 7%) reduces microvascular complications and some composite macrovascular outcomes compared with more relaxed glycaemic control, supporting the principle that improving glycaemic control is beneficial, though benefits must be balanced against risks.[4][13][16][21] Major guidelines for diabetes care (e.g., ADA Standards of Care) endorse the classification of diabetes into type 1 and type 2, stress the importance of individualized glycemic targets, and integrate diet, physical activity, pharmacologic therapy, and cardiovascular risk management as core components of care.[2][3][11]
- Contradicts
- Evidence does not support viewing type 1 and type 2 diabetes as a single, homogeneous condition or assuming they can be managed interchangeably. Type 1 diabetes guidelines emphasize lifelong dependence on exogenous insulin due to autoimmune beta‑cell destruction; dietary changes alone cannot reverse or cure type 1 diabetes, and complete insulin withdrawal is not considered safe or evidence‑based.[1][5][9][19][22] In contrast, remission is documented and increasingly recognized for type 2 diabetes, typically via significant weight loss and intensive lifestyle or metabolic interventions, highlighting a fundamental difference in reversibility.[0][15][20][23] The BMJ meta‑analysis on intensive glycaemic control in type 2 diabetes shows that while tighter control can reduce some vascular endpoints, it significantly increases severe hypoglycaemia (about 30% higher risk), indicating that very aggressive glycaemic targets are not universally beneficial and may be harmful for many patients.[4][13][16][21][24] These data contradict any simplistic claim that “lower is always better” for glucose in all people with type 2 diabetes. Umbrella reviews and guidelines also show heterogeneity in response to diets for type 2 diabetes; no single dietary pattern is universally superior, and the certainty of evidence for remission and long‑term outcomes varies from low to moderate, underscoring that strong, uniform claims about diet‑based cures are not well supported.[0][20][23]
- Mainstream view
- Mainstream medical and scientific consensus is that type 1 and type 2 diabetes are distinct diseases that share chronic hyperglycaemia and elevated cardiometabolic risk but differ in etiology, typical age of onset, and treatment approach. Type 1 diabetes is primarily an autoimmune, insulin‑deficient condition requiring lifelong insulin therapy, structured self‑management education, frequent glucose monitoring, and comprehensive risk‑factor control; remission or cure through diet alone is not recognized.[1][5][9][19][22] Type 2 diabetes is characterized by insulin resistance and relative insulin deficiency, strongly linked to obesity and lifestyle factors. Evidence‑based management emphasizes lifestyle changes (dietary modification, physical activity, weight loss), metformin and other glucose‑lowering agents, and individualized escalation including insulin if needed.[2][3][20] For type 2 diabetes, high‑quality reviews and guidelines now acknowledge that remission is achievable in a subset of patients, particularly with substantial, sustained weight loss via very low‑energy diets, bariatric surgery, or intensive lifestyle/metabolic programs, but long‑term durability and applicability to all patients remain limited.[0][15][20][23] Major guidelines endorse individualized glycaemic targets (often HbA1c
“Type 1 and 2 Diabetes”
Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Neurological Disorders and Neuropathy.
Neurological Disorders and Neuropathy
- Supports
- The only indexed paper directly focused on neurological disorders is the systematic review on citicoline in neurological diseases, which reports potential benefits for cognition, dementia progression, stroke recovery, and animal models of nerve damage and neuropathy, where citicoline stimulated nerve regeneration and reduced pain . [18][21][22] This provides some mechanistic and preclinical support for a role of citicoline in neuropathic processes and neuroprotection, but mainly in animal and non‑peripheral human neuropathy contexts . [19] The ESPEN guideline on clinical nutrition in inflammatory bowel disease and the ASPEN‑FELANPE clinical nutrition guideline emphasize that appropriate nutritional support can prevent or correct deficiencies (such as B vitamins) that are known contributors to some neuropathies, indirectly supporting the general concept that clinical nutrition and metabolic management are relevant to neurological complications, including neuropathy . [6][7][8] Outside the indexed list, mainstream academic literature reports that certain nutritional factors (e. g. , vitamin B12, B1, folate, copper) are established, evidence‑based contributors to neuropathy when deficient, and that correcting these deficiencies can improve or stabilize neuropathic symptoms; this supports a limited but genuine role of nutrition in some neuropathies and neurological disorders. High‑quality guidelines in neurology (e. g. , for diabetic neuropathy and peripheral neuropathic pain) consistently support pharmacologic treatments such as duloxetine, tricyclic antidepressants, certain anticonvulsants and topical agents, which indirectly confirms that neuropathy is a well‑defined neurological condition responsive to evidence‑based medical therapy, but this does not specifically validate any broad influencer claim beyond that general point. [20]
- Contradicts
- The citicoline systematic review explicitly concludes that, although citicoline shows neuroprotective and cognitive benefits in some settings, its clinical effect is unclear or modest in major neurological conditions like traumatic brain injury and stroke, and it relies heavily on animal data for neuropathy and nerve regeneration . [18][21][22] This means robust randomized human data for citicoline in peripheral neuropathy, chronic neuropathic pain, or generalized "neurological disorders" are lacking or inconclusive, which contradicts any strong, broad claims that citicoline is an established treatment for neuropathy or a wide range of neurological diseases . [20] The ASPEN‑FELANPE nutrition guideline and the ESPEN IBD nutrition guideline focus on enteral/parenteral nutrition and disease‑specific nutritional management, and they do not recommend citicoline or similar supplements as standard therapy for neuropathy or neurological disorders; their emphasis is on preventing and treating malnutrition rather than on neuroenhancement . [7][8][19] More broadly, major neurology and pain guidelines do not list citicoline as a first‑line or guideline‑supported treatment for peripheral neuropathy or neuropathic pain, which contradicts any suggestion that it is mainstream or strongly evidence‑based for these indications. [6] Existing evidence for many proposed "neuropathy supplements" (including various neuroprotective agents) is often limited to small trials, animal studies, or uncontrolled series, and systematic reviews frequently highlight heterogeneity and high risk of bias, contradicting influencer narratives that imply strong, generalized efficacy across neuropathic and other neurological disorders.
- Mainstream view
- The mainstream medical position is that neurological disorders and neuropathies are heterogeneous conditions caused by diverse mechanisms (metabolic, autoimmune, genetic, toxic, compressive, infectious), and management must be etiology‑specific and guideline‑driven rather than based on broad, one‑size‑fits‑all supplements. [6] For neuropathy, major guidelines support first identifying and treating reversible causes (e. [7] g. , diabetes, vitamin B12 or B1 deficiency, toxin exposure), optimizing disease control, and then using evidence‑based pharmacologic therapies for neuropathic pain and functional impairment; nutritional support is recommended when deficiencies or malnutrition are documented but is not a stand‑alone cure. Citicoline is viewed as a potentially neuroprotective and cognitive‑enhancing agent with promising but mixed evidence in certain neurological disorders (such as stroke and dementia), and the clinical data for peripheral neuropathy and generalized neuropathic pain remain preliminary, largely preclinical, and insufficient for routine guideline‑level recommendation . [8][18][19][20][21][22] Overall, mainstream neurology accepts neuropathy as a serious neurological disorder with validated diagnostic and therapeutic pathways, but it does not endorse broad claims that citicoline or similar single agents reliably treat or reverse "neurological disorders and neuropathy" without strong, indication‑specific evidence. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim).
“Neurological Disorders and Neuropathy”
Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care)
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to advertise Post Covid Long Haul Symptoms as within their scope of practice.
Post Covid Long Haul Symptoms
- Supports
- High-quality evidence clearly supports the existence of post-acute sequelae after SARS-CoV-2 infection, commonly termed Long COVID, post COVID-19 condition, or post-acute sequelae of SARS-CoV-2 infection (PASC). [23][24][25][26][27][29][30] Multiple large cohort studies, systematic reviews, and guidelines document persistent, relapsing, or new symptoms affecting multiple organ systems for weeks to years after acute infection. Clinical and guideline definitions: Major public health bodies (WHO, CDC, NIH, NICE and other national guidelines) define post-COVID or Long COVID as ongoing, relapsing, or new symptoms that begin after the acute infection and persist beyond a defined time window (typically ≥4 weeks, often ≥3 months) without an alternative explanation. These definitions consistently describe a wide range of symptoms including fatigue, dyspnea, cognitive dysfunction (“brain fog”), chest pain, palpitations, dysautonomia, and mental health symptoms, among others. Symptom range and organ systems: Narrative and scoping reviews and recent basic and clinical research show that post-acute sequelae can affect respiratory, cardiovascular, neurological, psychiatric, digestive, urinary, dermatologic and hematologic systems. Long COVID is described as a multisystem, heterogeneous condition with clusters of symptoms rather than a single uniform syndrome. Prevalence and burden: Large observational cohorts and meta-analyses report substantial prevalence of persistent symptoms after COVID-19. Estimates vary with methodology and population, but many studies find that roughly 10–30% of previously infected adults report ongoing symptoms at ≥4–12 weeks, with higher proportions in hospitalized and more severely ill groups. Some meta-analyses pooling global data report even higher prevalence in selected cohorts, and CDC surveillance data indicate that around 1 in 10 adults with prior COVID-19 in the US currently experience Long COVID symptoms. Duration and long-term outcomes: Prospective cohort studies using large health system datasets show that elevated risks for multiple post-acute sequelae can persist for at least 1–2 years after infection, particularly among those who were hospitalized, with some evidence up to 3 years. [28] These risks include respiratory symptoms, cardiovascular events (e. g. , arrhythmias, ischemic heart disease), metabolic disturbances (e. g. , new-onset diabetes), neurocognitive impairment, mental health conditions, and fatigue syndromes. Risk factors: Large multi-center studies (including those aligned with NIH RECOVER) identify risk factors for PASC such as older age, female sex, comorbidities (e. g. , obesity, diabetes, cardiovascular disease), severe acute COVID (including ICU care), and social determinants of health. Vaccination prior to infection consistently reduces but does not eliminate Long COVID risk. Children and adolescents: Pediatric-focused reviews and consensus statements describe post-acute sequelae in children, including definitions requiring at least one persistent physical symptom for ≥12 weeks after confirmed infection, affecting daily functioning and potentially fluctuating over time. Conditions such as multisystem inflammatory syndrome in children (MIS-C) are recognized as serious post-acute complications. Functional impact: Public health surveillance and clinical cohorts show that Long COVID frequently leads to significant limitations in daily activities, employment, and quality of life, with a notable proportion of patients reporting serious activity limitation. Overall, high-quality evidence from large cohort studies, systematic reviews, national surveillance, and major clinical guidelines strongly supports the existence of post-COVID long-haul symptoms as a significant, multisystem, infection-associated chronic condition.
- Contradicts
- Despite strong evidence that post-COVID long-haul symptoms exist, there are important areas where evidence is limited, heterogeneous, or contradictory. [24][27][29] Prevalence uncertainty: Estimates of Long COVID prevalence vary widely by study design, case definition, follow-up duration, and population. [30][7][8][31] Some well-controlled studies using matched cohorts and strict definitions report lower prevalence than earlier, more permissive surveys. This heterogeneity means that specific numerical claims (for example, that a fixed percentage of all infected people will develop Long COVID) are not uniformly supported across all high-quality studies. Causality and mechanisms: While epidemiologic associations between SARS-CoV-2 infection and later symptoms are robust, definitive mechanisms (viral persistence, autoimmunity, microvascular damage, dysautonomia, immune dysregulation, etc. [23][25][26] ) remain under active investigation. For many symptom clusters, causality and pathophysiology are still incompletely defined, and different studies support different dominant mechanisms. Attribution and overlap with other conditions: Some studies highlight substantial overlap between Long COVID symptom profiles and other post-infectious syndromes (such as ME/CFS), anxiety and depressive disorders, and consequences of critical illness or hospitalization. [28] In some cohorts, the excess
“Post Covid Long Haul Symptoms”
Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care)
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Unexplained fatigue.
Unexplained fatigue
No specific health claims of theirs were cross-checked against the literature.
“Unexplained fatigue”
Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care)
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Functional Medicine.
Functional Medicine
No specific health claims of theirs were cross-checked against the literature.
“Functional Medicine”
Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care)
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Endocrinology.
Endocrinology
No specific health claims of theirs were cross-checked against the literature.
“Endocrinology”
Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care)
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure Gastroenterology.
Gastroenterology
No specific health claims of theirs were cross-checked against the literature.
“Gastroenterology”
Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care)
John David Ratcliffe is not licensed or approved by Virginia Board of Medicine, Chiropractic Advisory Board to diagnose, treat, or cure PrimaryCare.
PrimaryCare
No specific health claims of theirs were cross-checked against the literature.
“PrimaryCare”
Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care)
Manipulation
False Authority
transcript · cited
Ratcliffe uses the term 'physicians' to describe himself as a Chiropractor (DC), conflating his narrow chiropractic license with the broad authority of an MD/DO. This is a classic false authority tactic to imply he can treat systemic disease like a medical doctor. Likely motive: To bypass patient skepticism about chiropractors treating systemic diseases (MS, Diabetes, Autoimmune) by borrowing the authority of the term 'physician'.
“one of an elite group of physicians to also hold both a Diplomate in Clinical Nutrition and become a Certified Functional Medicine Practitioner”
Fear Mongering
transcript · cited
Frames standard medical diagnoses as insufficient and implies a hidden 'root cause' (often linked to supplements/labs he sells) that only he can find. This creates anxiety that standard care is failing the patient. Likely motive: To drive patients away from standard insurance-covered care and into his cash-pay 'Functional Medicine' roadmap for supplements and labs.
“We try to analyze the Why's of your specific disease process, rather than simply leave you with a diagnosis.”
Urgency / Scarcity
transcript · cited
Uses a 'free' consultation as a high-pressure sales funnel entry point to qualify patients for expensive cash-pay services, creating a false sense of exclusivity ('we require') while actually just screening for high-value buyers. Likely motive: To filter for patients willing to pay for non-covered 'Functional Medicine' services without upfront cost barriers.
“Before accepting new patients, we require a complimentary phone consultation to ensure we can best support your health goals.”
Sales Funnel Motive
transcript · cited
Explicitly states services are cash-pay, framing insurance rejection as a badge of honor ('unrivaled at an affordable price') rather than a red flag that the service is non-standard. This is a direct sales funnel for high-margin supplements and labs. Likely motive: To monetize patients who are desperate for 'better' care and willing to pay out-of-pocket for unproven protocols.
“This visit is not covered by insurance.”
Commerce & grift map
Ratcliffe uses 'elite physician' false authority to attract patients with systemic diseases (MS, Diabetes, Autoimmune) that are out-of-scope for his DC license. He then funnels them into a cash-pay 'Functional Medicine Roadmap' that explicitly excludes insurance, likely monetizing high-margin supplements and lab tests. The pattern is: scare content about 'root causes' -> cash-pay 'not covered' visit -> unproven protocol -> supplement/lab sales.
No FTC-style compensation disclosure
compensationDisclosures · scan
Cash-pay 'Functional Medicine Roadmap' and 'Initial Interview' not covered by insurance, likely monetizing supplements and labs.
wellness_plan
Host self-funnel around guest content
guestCollaboration · selfFunnel
Host routes viewers to their own consult/booking links around the guest segment.
How the money flows
- Paid wellness plan / membershipUndisclosed Cash-pay 'Functional Medicine Roadmap' and 'Initial Interview' not covered by insurance, likely monetizing supplements and labs. “This visit is not covered by insurance.”
“This visit is not covered by insurance.”
Credentials & scope
Glossary: Chiropractor (“Dr.”)
Stated: Chiropractor
Verified against the federal provider registry: D.C. · Chiropractor, Rehabilitation · VA license 0104001753.
Ratcliffe holds a Chiropractor license but advertises himself as a 'physician' treating systemic diseases (MS, Diabetes, Autoimmune) that are strictly outside the Virginia Chiropractic Board's scope. This is credential inflation: using a narrow musculoskeletal license to imply broad medical competence.
- DC, Doctor of Chiropractic
A state-licensed professional degree focused on spinal adjustment and musculoskeletal/nervous system care. In Virginia, the scope is limited to evaluation/treatment of musculoskeletal conditions, NOT general internal medicine, prescription pharmacology, or primary disease management of systemic illnesses.
Virginia Board of Medicine, Chiropractic Advisory Board: Scope limited to musculoskeletal/nervous system via spinal adjustment. Cannot diagnose/treat systemic disease (MS, Diabetes, Autoimmune) or prescribe drugs.
Permitted scope vs advertised
Virginia Board of Medicine, Chiropractic Advisory Board · Confidence: medium
In Virginia, chiropractors are licensed to diagnose and treat disorders of the musculoskeletal system and their effects on the nervous system and general health, primarily using manual spinal manipulation and other noninvasive, non-drug treatments.[6] Chiropractic practice in Virginia does not include the use of drugs or surgery and is not a general medical license to practice medicine or medical specialties such as endocrinology or gastroenterology.[6][2] Chiropractors may use physical, X‑ray, and certain laboratory tests to analyze a patient’s condition, provide lifestyle and nutritional advice, and refer patients who need drugs, surgery, or broader medical management to other health care professionals.[6]
What this license permits
- Spinal adjustment and manipulation
- Musculoskeletal evaluation and treatment
- Soft-tissue and rehabilitative care
- Headache care within musculoskeletal scope
18 of 19 advertised activities fall outside permitted scope.
| Advertised | Verdict |
|---|---|
| Listed service Autoimmune and inflammatory disorders (MS, RA, Thyroid, SLE, Etc.) Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929 (prohibition on practicing medicine without a license) Systemic autoimmune and endocrine diseases such as MS, RA, thyroid disorders, and SLE are complex medical conditions outside the musculoskeletal-focused chiropractic scope and require medical management with drugs and specialized care that chiropractic practice in Virginia does not include.[6] | Outside scope |
| Listed service Type 1 and 2 Diabetes Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929 Diagnosing diabetes, an endocrine and metabolic disease that requires laboratory testing, pharmacologic management (including insulin), and ongoing medical oversight, exceeds the musculoskeletal and non-drug scope described for chiropractors in Virginia.[6] | Outside scope |
| Listed service Gut dysfunction (gas, bloating, IBS, SIBO, IBD, GERD/reflux, celiac) Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary Diagnosing systemic gastrointestinal diseases such as IBS, IBD, celiac disease, and GERD involves medical gastroenterology and often drugs, endoscopy, and biopsies, which are not affirmatively authorized within the Virginia chiropractic musculoskeletal-focused, non-surgical, non-drug scope.[6] | Outside scope |
| Listed service Depression/Anxiety Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929 Primary diagnosis and management of psychiatric conditions such as depression and anxiety fall within the practice of medicine or psychology, not the musculoskeletal-centered chiropractic scope described for Virginia chiropractors.[6][2] | Outside scope |
| Diagnosing and treating systemic autoimmune diseases (MS, RA, SLE) and endocrine disorders (Thyroid) as a Chiropractor. Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929 Providing primary diagnosis and treatment for systemic autoimmune and endocrine diseases, which customarily require medical drugs, immunomodulators, and endocrine therapies, is not affirmatively permitted in the Virginia chiropractic scope limited to musculoskeletal disorders and non-drug care.[6] | Outside scope |
| Offering to treat Type 1 (insulin-dependent) and Type 2 Diabetes, which is outside the scope of a DC license. Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929 Managing Type 1 and Type 2 diabetes involves prescribing and adjusting medications such as insulin and monitoring systemic metabolic status, all of which are forms of practicing medicine that are not included in the non-drug chiropractic scope in Virginia.[6][2] | Outside scope |
| Diagnosing and treating systemic gastrointestinal diseases (IBD, Celiac, SIBO) and GERD. Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary Systemic gastrointestinal disorders like IBD, celiac disease, and GERD require medical gastroenterology evaluation, invasive diagnostics, and pharmacologic therapy, which are beyond the musculoskeletal and noninvasive scope granted to Virginia chiropractors.[6] | Outside scope |
| Functional Medicine for Autoimmune/Neurological Disorders Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929 Advertising functional medicine management of systemic autoimmune and neurological disorders implies broad medical diagnostic and therapeutic authority over systemic disease that is not affirmatively authorized within Virginia’s chiropractic scope restricted to musculoskeletal disorders and non-drug care.[6] | Outside scope |
| Treatment of Type 1 and 2 Diabetes Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary; Code of Virginia § 54.1-2929 Treating diabetes, particularly Type 1 insulin-dependent diabetes, is medical endocrinology care involving prescription drugs and systemic disease management beyond the scope of Virginia chiropractors, who are limited to non-drug musculoskeletal care.[6] | Outside scope |
| Treatment of MS, RA, SLE (Autoimmune) Rule: Virginia Health Workforce Development Authority – Chiropractor scope summary MS, RA, and SLE are complex systemic autoimmune and neurological/rheumatologic diseases usually treated with immunosuppressive and specialty medical therapies, not within the musculoskeletal, non-drug chiropractic scope in Virginia.[6] | Outside scope |
| Listed service Neurological Disorders and Neuropathy Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
| Listed service Post Covid Long Haul Symptoms Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
| Listed service Unexplained fatigue Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
| Listed service Functional Medicine Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
| Listed service Endocrinology Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
| Listed service Gastroenterology Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
| Listed service PrimaryCare Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
| Using the term 'physicians' to describe himself as a Chiropractor, conflating his narrow license with the broad authority of an MD/DO. Rule: Virginia Chiropractic Practice Act (scope limited to musculoskeletal/spine care) Not listed among permitted DC scope activities under the governing practice act. | Outside scope |
Sources: Virginia Health Workforce Development Authority – Chiropractor description and scope, Virginia Board of Medicine – Regulated Professions: Chiropractor (official), Virginia Register – Regulations referencing Code of Virginia § 54.1-2929 (official), 30-16-18. Scope of practice; chiropractic assistants (official)
Scope comparison mirror
Side-by-side view of the archived marketing homepage and what a Chiropractor scope permits near Sterling, VA. Open the mirror for the full comparison: archive on the left, permitted scope and licensed-care paths on the right.
Mirror generated 2026-07-14 14:47 UTC. The archive pane loads styles and images from the intake snapshot.
9 licensed-care paths linked for out-of-scope claims.
When the service is also outside their license
This pattern gets sharper when the service routed to your FSA or HSA also sits outside the practitioner's licensed scope. A provider advertising to diagnose or treat conditions their state board does not authorize is already operating past the edge of their license. Pair that with a cash-pay, FSA or HSA funded model that keeps the work away from any insurer or government program, and there is no claims reviewer, no audit trail, and no payer left to ask whether the care was appropriate or even within the provider's remit. The tax advantaged dollars do the paying, the patient carries the substantiation, and the scope question never reaches anyone with the authority to raise it.
Validated associated properties
Surfaces tied to this Doc Bro by domain, branding, or funnel routing. Third-party platforms are labeled as routes, not as owned properties.
Analyzed
- OwnedOfficial site (functionalmedicinenorthernvirginia.com)
Tip the jar
Report useful? Optional tips help keep scans, archives, and literature cross-checks running. They never change conclusions.
Submission tf5KVAHsSl94wMCcN6FAO
Fight disinformation
Log a public thread where John David Ratcliffe is spreading nonsense, get a copy-paste reply with this report link.
Reply snippets
Before you buy the protocol: Dr. Trust Me Bro fact-checked John David Ratcliffe's claims with peer-reviewed sources, https://drtrustmebro.com/analyze/tf5KVAHsSl94wMCcN6FAO. White-coat charisma isn't evidence.
Full DTMB scan on John David Ratcliffe: https://drtrustmebro.com/analyze/tf5KVAHsSl94wMCcN6FAO
Drop these in YouTube comments, Reddit threads, and forums, link back to this scan, not vibes.
Recent mentions (this doc)
- YouTube
Functional Medicine Case Review Jemma 2
One of John David Ratcliffe's own recent posts. The comment thread is where this pitch spreads, reply there with the report link.
- YouTube
Functional Medicine Case Review Jemma 1
One of John David Ratcliffe's own recent posts. The comment thread is where this pitch spreads, reply there with the report link.
- YouTube
Functional Medicine Case Review Jemma 2
One of Johan S. Urena Hernandez's own recent posts. The comment thread is where this pitch spreads, reply there with the report link.
- YouTube
Functional Medicine Case Review Jemma 1
One of Johan S. Urena Hernandez's own recent posts. The comment thread is where this pitch spreads, reply there with the report link.
Nudge the Doc Bro
We email a public contact address from their site so John David Ratcliffe can review this dossier and dispute anything we got wrong.
Know someone who can help?
If you think someone has firsthand information about John David Ratcliffe, send them an encouraging note. We email a short, respectful message with this report and clear instructions on how to write in, on the record or anonymously.
Whambulance
Challenge this scan or Wall of Fame entry for John David Ratcliffe. Public log, not legal arbitration.
Public challenge log
No posted Wall of Fame challenges linked yet.
Challenges are public on the Wall of Fame card. DTMB does not remove entries for hurt feelings, primary sources or copy corrections only.
File a challenge
Include in your email:
- Doc Bro ID: 9r7ChiT9ZGJPK033qxjvV
- Wall entry: /influencer/9r7ChiT9ZGJPK033qxjvV
- Analysis ID: tf5KVAHsSl94wMCcN6FAO
- Source: https://functionalmedicinenorthernvirginia.com/
- Why this entry or scan should change
- Supporting links (one per line)
- Your business email (for verified disputes)
Verified challenges are posted publicly on the report. Public log, not legal arbitration.
Citations
Peer-reviewed and index sources cited in this report.
- [1] Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
- [2] Systemic lupus erythematosus: state of the art on clinical practice guidelines
- [3] Antigen-based immunotherapy for autoimmune disease: current status
- [4] Thank you to the reviewers of Rheumatology Advances in Practice 2022
- [5] Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission.
- [6] Guideline-Driven Management of Hypertension: An Evidence-Based Update.
- [7] ASPEN-FELANPE Clinical Guidelines.
- [8] ESPEN guideline: Clinical nutrition in inflammatory bowel disease.
- [9] Current Management of Type 1 Diabetes in Children: Guideline-based Expert Opinions and Recommendations
- [10] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.
- [11] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.
- [12] 14. Children and Adolescents: Standards of Care in Diabetes-2024.
- [13] When Is Parenteral Nutrition Appropriate?
- [14] Integrated Approaches in the Management of Gastrointestinal Disorders: A Biopsychosocial Perspective
- [15] Functional Bowel Disorder Management in Routine Practice with Tips for Hot Topics: Expert Opinion Review
- [16] Symptoms of Functional Intestinal Disorders Are Common in Patients with Celiac Disease Following Transition to a Gluten-Free Diet
- [17] Irritable bowel syndrome: dietary interventions.
- [18] Application of Citicoline in Neurological Disorders: A Systematic Review.
- [19] Neuroenhancement and neuroprotection by oral solution citicoline in non-arteritic ischemic optic neuropathy as a model of neurodegeneration: A randomized pilot study
- [20] Cytidine 5′-diphosphocholine administration prevents peripheral neuropathic pain after sciatic nerve crush injury in rats
- [21] A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy
- [22] Preclinical evidence for the anxiolytic- and antidepressant-like effects of citicoline and imipramine in the sciatic nerve-ligated mice
- [23] Acute and post-acute sequelae of SARS-CoV-2 infection: a review of risk factors and social determinants
- [24] Post-acute Sequelae in COVID-19 Survivors: an Overview
- [25] Post-acute Sequelae of SARS-CoV-2 Infection: A Neglected Public Health Issue
- [26] Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras
- [27] Three-year outcomes of post-acute sequelae of COVID-19
- [28] Post-infectious and post-acute sequelae of critically ill adults with COVID-19
- [29] Postacute sequelae of COVID-19 at 2 years
- [30] A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings
- [31] PubMed indexed study